生物降解药物涂层冠脉支架系统

Search documents
赛诺医疗收盘上涨13.72%,滚动市盈率2342.49倍,总市值143.83亿元
Sou Hu Cai Jing· 2025-08-15 12:23
最新一期业绩显示,2025年一季报,公司实现营业收入1.01亿元,同比10.75%;净利润296.93万元,同 比277.50%,销售毛利率59.66%。 8月15日,赛诺医疗今日收盘34.57元,上涨13.72%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到2342.49倍,创1230天以来新低,总市值143.83亿元。 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均56.58倍,行业中值39.97倍,赛诺医疗排 名第123位。 截至2025年一季报,共有1家机构持仓赛诺医疗,其中基金1家,合计持股数20.34万股,持股市值0.02亿 元。 赛诺医疗科学技术股份有限公司的主营业务是高端介入医疗器械研发、生产、销售。公司的主要产品是 生物降解药物涂层冠脉支架系统、药物洗脱支架系统、非顺应性PTCA球囊扩张导管、PTCA球囊扩张 导管、非顺应性球囊扩张导管、冠脉球囊扩张导管、冠状动脉棘突球囊扩张导管、延长导管、颅内药物 洗脱支架系统、颅内取栓支架、颅内球囊扩张导管、负压吸引泵、一次性使用无菌吸引延长管、远端通 路导管、颅内血栓抽吸导管、微导管、远端通路导引导管、导引导管、桡动脉通路导引系 ...
赛诺医疗收盘上涨6.70%,滚动市盈率992.69倍,总市值60.95亿元
Sou Hu Cai Jing· 2025-08-01 14:50
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sino Medical, indicating a significant increase in net profit and a high PE ratio compared to industry averages [1][2] - As of August 1, Sino Medical's stock closed at 14.65 yuan, up 6.70%, with a rolling PE ratio of 992.69, marking a new low in 1121 days and a total market capitalization of 6.095 billion yuan [1] - The average PE ratio for the medical device industry is 53.65, with a median of 37.22, positioning Sino Medical at 121st in the industry ranking [1][2] Group 2 - For Q1 2025, Sino Medical reported revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.9693 million yuan, reflecting a substantial year-on-year growth of 277.50% [2] - The company's gross profit margin stands at 59.66%, indicating strong profitability relative to its revenue [2] - As of March 31, 2025, Sino Medical had 11,044 shareholders, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]
赛诺医疗收盘上涨1.37%,滚动市盈率850.40倍,总市值52.21亿元
Sou Hu Cai Jing· 2025-07-23 12:47
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sainuo Medical, indicating a significant increase in net profit and a high PE ratio compared to industry averages [1][2] - As of March 31, 2025, Sainuo Medical had 11,044 shareholders, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, and sales of high-end interventional medical devices, with key products including biodegradable drug-coated coronary stent systems and various types of balloon dilation catheters [1] Group 2 - In the first quarter of 2025, Sainuo Medical reported revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.9693 million yuan, reflecting a substantial year-on-year growth of 277.50% [2] - The company's gross profit margin stood at 59.66%, indicating strong profitability relative to its revenue [2] - Sainuo Medical's rolling PE ratio is 850.40, significantly higher than the industry average of 53.52 and the median of 37.14, positioning it at 121st in the industry ranking [2]
赛诺医疗收盘上涨7.73%,滚动市盈率821.26倍,总市值50.43亿元
Sou Hu Cai Jing· 2025-07-18 11:23
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Sino Medical, noting its significant increase in stock price and high PE ratio compared to industry averages [1][2] - As of July 18, Sino Medical's stock closed at 12.12 yuan, up 7.73%, with a rolling PE ratio of 821.26, marking a new low in 285 days and a total market capitalization of 5.043 billion yuan [1] - The average PE ratio for the medical device industry is 52.34, with a median of 36.99, placing Sino Medical at the 121st position in the industry ranking [1][2] Group 2 - For Q1 2025, Sino Medical reported revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.9693 million yuan, reflecting a substantial year-on-year growth of 277.50% [2] - The company's gross profit margin stands at 59.66%, indicating strong profitability relative to its revenue [2] - As of March 31, 2025, Sino Medical had 11,044 shareholders, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]
赛诺医疗收盘下跌1.62%,滚动市盈率739.95倍,总市值45.43亿元
Sou Hu Cai Jing· 2025-07-07 22:03
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sainuo Medical, indicating a high PE ratio compared to industry averages [1][2] - As of the first quarter of 2025, Sainuo Medical reported a revenue of 101 million yuan, representing a year-on-year increase of 10.75%, and a net profit of 2.97 million yuan, showing a significant year-on-year growth of 277.50% [2] - The company's gross profit margin stands at 59.66%, indicating strong profitability relative to its revenue [2] Group 2 - Sainuo Medical's current PE ratio is 739.95, significantly higher than the industry average of 51.42 and the median of 37.44, placing it at the 121st position in the industry ranking [1][2] - The total market capitalization of Sainuo Medical is 4.543 billion yuan, reflecting its valuation in the medical device sector [1] - The company specializes in high-end interventional medical devices, with key products including biodegradable drug-coated coronary stent systems and various types of balloon catheters [1]
赛诺医疗收盘下跌1.34%,滚动市盈率750.79倍,总市值46.10亿元
Sou Hu Cai Jing· 2025-07-03 09:13
Company Overview - Sino Medical's closing price on July 2 was 11.08 yuan, down 1.34%, with a rolling PE ratio of 750.79 times and a total market value of 4.61 billion yuan [1] - The company specializes in the research, production, and sales of high-end interventional medical devices, including biodegradable drug-coated coronary stent systems and various types of balloon dilatation catheters [1] Financial Performance - In the first quarter of 2025, the company achieved operating revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.97 million yuan, a year-on-year increase of 277.50% [2] - The sales gross margin for the same period was 59.66% [2] Shareholder Information - As of March 31, 2025, the number of shareholders for Sino Medical was 11,044, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 51.29 times, with a median of 37.02 times, placing Sino Medical at the 121st position in the industry ranking [1] - The company's static PE ratio is 3077.74 times, and its price-to-book ratio is 5.30 [2]
赛诺医疗收盘下跌1.75%,滚动市盈率724.36倍,总市值44.48亿元
Sou Hu Cai Jing· 2025-06-26 11:39
Core Viewpoint - Sino Medical reported a closing price of 10.69 yuan, down 1.75%, with a rolling PE ratio of 724.36 times, and a total market value of 4.448 billion yuan [1] Company Summary - Sino Medical's main business focuses on the research, development, production, and sales of high-end interventional medical devices [1] - Key products include biodegradable drug-coated coronary stent systems, drug-eluting stent systems, non-compliant PTCA balloon dilatation catheters, and various other specialized medical devices [1] Financial Performance - For Q1 2025, the company achieved an operating income of 101 million yuan, representing a year-on-year increase of 10.75% [2] - The net profit for the same period was 2.9693 million yuan, showing a significant year-on-year increase of 277.50% [2] - The sales gross margin stood at 59.66% [2] Industry Comparison - The average PE ratio for the medical device industry is 49.45 times, with a median of 35.92 times, positioning Sino Medical at 121st place within the industry [1] - The company's static PE ratio is 296.94 times, and the price-to-book ratio is 5.11 [2]